Pulmonary Arterial Hypertension

The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.

Latest News
July 24th 2024

CTEPH Treatment, Management Varies Widely Across Globe

July 17th 2024

Proteomics Promise: Not Yet Realized in Early Prediction of HDP

July 10th 2024

Integrating Maternal BP Checks in Pediatric Visits Enhances Outcomes

July 3rd 2024

Optimizing Pulmonary Hypertension Treatment With Digital Twin Models

June 27th 2024

Hypertension Disorders of Pregnancy Largely Persist in the Postpartum Period

Video Interviews
View All
June 12th 2024

Addressing Unmet Needs in the PAH Landscape

June 12th 2024

Optimizing PAH Care Delivery for Better Outcomes

June 5th 2024

Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches

May 29th 2024

Overcoming Barriers to Better Patient Outcomes in PAH

May 22nd 2024

FDA Approves Sotatercept for Pulmonary Arterial Hypertension

May 15th 2024

Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

May 6th 2024

A New Era in PAH Treatment?

May 6th 2024

Breaking Down the PAH Cost Burden

May 3rd 2024

Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

May 3rd 2024

Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management

More News

illustration of seizure | Image Credit: Teeradej-stock.adobe.com
June 25th 2024

Angiotensin Receptor Blockers Associated With Lower Epilepsy Risk in Hypertension

Karen Jacobson-Sive
Losartan may help stop the epileptic process in certain patients with hypertension.
Asian man with hypertension | Image Credit: jeffy1139-stock.adobe.com
June 18th 2024

Community Practitioner–Led Hypertension Program Yields Strong Results

Jared Kaltwasser
A Chinese study shows hypertension management led by nonphysicians can be safe and effective.
chlorthalidone | Image Credit: luchschenF-stock.adobe.com
June 12th 2024

Chlorthalidone May Be More Appropriate Diuretic for Patients With Hypertension, Previous CV Event

AJMC Contributor
Patients receiving chlorthalidone had lower rates of major cardiovascular (CV) events and noncancer-related deaths vs those receiving hydrochlorothiazide.
hypertension | Image Credit: relif-stock.adobe.com
June 4th 2024

Same Hypertension, Different Levels of Portal Engagement, Disparities Research Shows

Gayle Turim Dickstein
When patients are treated in primary care for high blood pressure, sociodemographic factors sway the rates at which they access patient portals, investigators found. This could influence their hypertension outcomes.
Blood pressure measurement | Image credit: interstid - stock.adobe.com
May 27th 2024

Early BP Reduction Shows No Benefit in Acute Stroke, but Outcomes May Vary by Stroke Type

Kimberly Rath, PharmD
A study found that prehospital blood pressure (BP) reduction had no impact on functional outcomes among patients with undifferentiated acute stroke, but that it may decrease the odds of poor outcomes following hemorrhagic stroke.
Doctor holding heart | Image credit: Pana Studio - stock.adobe.com
May 14th 2024

CVD Outcomes Linked to Youth Hypertension, Study Shows

Gayle Turim Dickstein
Closer monitoring of youth hypertension could lessen the disease in adults, reducing overall costs and morbidity related to cardiovascular disease (CVD), new research shows.
PA and nursing home resident | Image Credit: InsideCreativeHouse - stock.adobe.com
May 2nd 2024

Initiating BP Medication Linked to Higher Fall, Fracture Risks in Nursing Home Residents

AJMC Contributor
Among over 60,000 nursing home residents who initiated antihypertensive medication, rates of excess fractures due to falls per 100 person-years were as high as 5 among certain patient groups, such as those with dementia and high blood pressure (BP).
Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension
May 1st 2024

New Therapeutic Frontiers in PAH

Ronald Oudiz, MD, FACP, FACC, FCCP
A cardiovascular specialist provides an overview of emerging therapies and targets in the PAH treatment space and how they address current unmet needs.
Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension
May 1st 2024

Evolving Guidelines for PAH Treatment

Ronald Oudiz, MD, FACP, FACC, FCCP
Ronald Oudiz, MD, FACP, FACC, FCCP, discusses the latest guidelines and recommendations for the treatment of pulmonary arterial hypertension (PAH) and how they differ from previous versions.
Older obese man receives checkup | Image Credit: © Studio Romantic - stock.adobe.com
April 20th 2024

Reducing Time Sitting Can Help Lower BP in Older Adults, Randomized Trial Finds

AJMC Contributor
The randomized trial found that reducing sitting time over a 6-month period was association with reduced systolic blood pressure (BP) among a group of older patients with obesity and high rates of hypertension.
Biomarker DNA Strand Medical Research | Image Credit: iQoncept - stock.adobe.com
April 10th 2024

Targeting MACC1 Offers Promising Therapeutic Strategy for PAH

Luke Halpern
Positive responses seen following experiments involving metastasis-associated in colon cancer 1 (MACC1) indicate that the biomarker can be used to better diagnose and treat patients with pulmonary arterial hypertension (PAH).
Patient measuring blood pressure with a digital monitor | Image credit: vchalup-stock.adobe.com
April 3rd 2024

Pandemic Care Gaps Associated With Loss of Hypertension Control, Study Finds

Jared Kaltwasser
Surprisingly, the investigators found people with uncontrolled hypertension before the pandemic actually had a slightly higher chance of getting their blood pressure under control during the crisis.
FDA Approved
March 26th 2024

FDA Approves Sotatercept, First-in-Class Treatment for Adults With PAH

Julia Bonavitacola
Adults with pulmonary arterial hypertension (PAH) have a new treatment available with the FDA approval of sotatercept (Winrevair; Merck), an activin signaling inhibitor biologic.
FDA Approved Products or Drugs | Image credit: Olivier Le Moal - stock.adobe.com
March 25th 2024

FDA Approves Macitentan, Tadalafil Combination Tablet for Pulmonary Arterial Hypertension

Rose McNulty
The approval, which marks the first for a once-daily, single-tablet combination therapy for pulmonary arterial hypertension, is based on findings from the phase 3 A DUE study.
Doctor Measuring Blood Pressure Of Patient | Image Credit: Andrey Popov - stock.adobe.com
March 18th 2024

Study Assessing Blood Pressure Interventions in Rural Black Population Finds Little Effect

Jared Kaltwasser
Two strategies were tried, but neither outperformed usual care.
Patient suffers from hypertension | Image Credit: vchalup - stock.adobe.com
March 14th 2024

Nearly One-Third of US Adults Report Hypertension, Show CDC Data

AJMC Contributor
Prevalence of hypertension remained 30% throughout the study period and was lower than expected, based on a lower threshold for hypertension endorsed by guidelines in 2017.
Hypertension on a blackboard slate | Image Credit: relif - stock.adobe.com
March 7th 2024

SNAP Benefits May Help Improve Adherence to Antihypertensive Medications

AJMC Contributor
Among food-insecure patients on antihypertensive medication, receiving assistance through the Supplemental Nutrition Assistance Program (SNAP) was associated with improvements in medication adherence.
Health care costs - Valeri Luzina - stock.adobe.com
February 28th 2024

Coverage Expansion, Other Economic Policies May Yield Positive Impact on Hypertension Management

AJMC Contributor
Researchers of the review are underscoring the potential for economic policies to improve the management of hypertension for the millions of people throughout the United States with the condition who are at risk for cardiovascular disease.
Businessman holding and touching floating stethoscope 3D rendering - sdecoret - stock.adobe.com
February 21st 2024

Digital Health Interventions Can Reduce Hypertension Among Disadvantaged Populations

Luke Halpern
Numerous strategies were proposed, including an emphasis on community-based interventions that can reduce psychological stressors associated with clinical settings.
Combination Therapies Provide Optimal Hypertensive Control in Patients Taking Ibrutinib
February 17th 2024

Combination Therapies Provide Optimal Hypertensive Control in Patients Taking Ibrutinib

Jared Kaltwasser
The retrospective study found patients on Bruton’s tyrosine kinase inhibitors are similar to the general population in the sense that it usually takes at least 2 anti-hypertensive drugs to control blood pressure.
Salt and heart disease | Image credit: Sharif - stock.adobe.com
February 12th 2024

Salt Substitute Reduces Incidence of Hypertension in Older Adults

Luke Halpern
For the first time, investigators found that the replacement of salt with a salt substitute not only reduced hypertension, but did not also increase hypotension, a key factor for older adults.
Weight gain or loss and high or low blood pressure concept | Image credit: shidlovski - stock.adobe.com
February 5th 2024

Bariatric Surgery Leads to Long-Term Hypertension Improvement in Patients With Obesity

Jared Kaltwasser
About half of patients receiving the procedure did not need medication to control their blood pressure after 5 years.
Medical | Image Credit: arbaz - stock.adobe.com
February 1st 2024

Researchers Emphasize Importance of Appropriate Kidney Transplant Management Based on PH Type

AJMC Staff
The group emphasizes the importance of management strategies that consider 5 types, or groups, of pulmonary hypertension (PH), including 4 types secondary to other conditions.
Heart and Lungs | Image credit: microscience - stock.adobe.com
January 22nd 2024

PAH Therapies Had Favorable Outcomes When Used in Patients With COVID-19

Julia Bonavitacola
A multidisciplinary approach is needed in patients with pulmonary arterial hypertension (PAH) who contract COVID-19, as they may experience worse outcomes.
Patients holding heart | Image credit: SewcreamStudio - stock.adobe.com
January 15th 2024

Changes in Trimethylamine N-Oxide Associated With Disease Severity, Prognosis in PAH

Julia Bonavitacola
The prognosis and disease severity of pulmonary arterial hypertension (PAH) was found to be associated with changes in trimethylamine N-oxide.
Human heart | Image credit: abhijith3747 - stock.adobe.com
January 9th 2024

AI Capable of Detecting PAH Associated With Congenital Heart Disease

Julia Bonavitacola
Congenital heart disease and pulmonary arterial hypertension (PAH) associated with congenital heart disease can be immediately detected using chest radiograph-based artificial intelligence (AI), a study found.
Pulmonary hypertension | Image credit: onephoto - stock.adobe.com
January 4th 2024

Oral Treprostinil, Selexipag Have Similar Efficacy in Patients With PAH

Julia Bonavitacola
Patients with pulmonary arterial hypertension (PAH) had similar efficacy and safety profile when taking either oral Treprostinil or selexipag, indicating that Treprostinil would be an adequate replacement.
Pulmonary Hypertension Text | image credit: tashatuvango - stock.adobe.com
December 31st 2023

Recurrent Pulmonary Hypertension After Balloon Pulmonary Angioplasty Is Rare, Study Finds

Kyle Munz
A retrospective study found that instances of recurrent pulmonary hypertension due to vascular reocclusion or restenosis were extremely uncommon after balloon pulmonary angioplasty.
Top 5 PAH Content 2023
December 25th 2023

Top 5 Most-Read PAH Content of 2023

Kyle Munz
This year’s top 5 most-read articles on pulmonary arterial hypertension (PAH) explored expert opinions on treatment approaches, data on newly emerging therapies, the impacts of alcohol, and more.
Calculator, stethoscope, medical bill | Image Credit: thanksforbuying - stock.adobe.com
December 19th 2023

Delayed PAH Diagnosis Increased Economic Burden, Study Says

Brooke McCormick
Increased pulmonary arterial hypertension (PAH) awareness and earlier screening in routine clinical practice could provide an opportunity for earlier treatment, resulting in reduced economic burden for payers, employers, and society at large.
12345678>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo